Delivery Order SPE2DB22D1106-SPE2DB25FFHA5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $11,758.26. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 8, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions,...
- The Defense Logistics Agency awarded a delivery order valued at $18,670.22 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe...
- The Defense Logistics Agency awarded a $37,116.52 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, which is not set-aside and carries firm fixed pricing, is scheduled for ultimate completion by August 29, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location in the same city....
- The Defense Logistics Agency awarded a $17,929.57 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including moderate-to-severe eczema, asthma, and chronic rhinosinusitis, making...
- The Defense Logistics Agency awarded a $21,976.95 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, chronic rhinosinusitis with nasal...
- The Defense Logistics Agency awarded a $54,501.62 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 27, 2025, with ultimate completion by August 28, 2025. This firm fixed-price, competitively awarded contract—without set-aside designation—will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic...
- The Defense Logistics Agency awarded a $6,274.10 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This non-set-aside, firm fixed price delivery order is scheduled for completion by July 21, 2025, with performance of work taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions such as atopic dermatitis, asthma, and eosinophilic esophagitis....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $11,573.00. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other...
- The Defense Logistics Agency awarded a $34,256.54 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This firm fixed-price contract, issued under a non-competitive set-aside designation, reflects DLA's pharmaceutical procurement needs for military and federal healthcare systems. The award represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $27,552.50 delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of June 6, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily indicated for moderate-to-severe atopic dermatitis, eosinophilic...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFHA5Delivery Order
The Defense Logistics Agency awarded a $30,588.59 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This firm fixed price contract, with an ultimate completion date of September 8, 2025, represents a competitively awarded, non-set-aside procurement issued under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps, making this delivery order part of the agency's ongoing pharmaceutical procurement for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's substantial $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical (contract number SPE2DX), which runs through December 2026 and serves as a comprehensive global pharmaceutical support vehicle. As a child contract under this IDC, the delivery order leverages the prime vendor's established capability to supply a wide range of brand-name and generic pharmaceuticals, specialty medications, and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.6k | 9/5/25 |